Introduction

A memory-first model of Alzheimer’s disease is useful in everyday clinical practice, but it is incomplete. Many patients with Alzheimer’s disease present with progressive episodic memory impairment. Some people first develop visual-spatial symptoms. Others may have language dysfunction or trouble with calculations. They might struggle with tasks, show executive dysfunction, or experience changes in behavior.

Non-amnestic presentations are particularly relevant in younger-onset Alzheimer’s disease. A patient in the fifth or sixth decade of life who can remember appointments may struggle with reading fluently, judging depth, using a computer interface, or retrieving words. This condition may not fit the typical public image of Alzheimer’s disease. That mismatch contributes to delayed diagnosis.

The main task for clinicians is to first define the clinical syndrome. Then, they must determine the likely underlying pathology. Posterior cortical atrophy describes a progressive syndrome dominated by posterior cortical dysfunction. Primary progressive aphasia describes a progressive syndrome dominated by language impairment. Both may relate to Alzheimer’s disease, but neither should be diagnosed as Alzheimer’s based only on clinical signs.

This distinction affects many important areas. It affects counseling and medication selection. It also determines eligibility for disease-modifying treatments. Additionally, it influences rehabilitation planning, safety assessments, and trial referrals. It also reduces diagnostic error in patients whose symptoms are real but not primarily amnestic.

Posterior Cortical Atrophy

Posterior cortical atrophy is a progressive neurodegenerative syndrome. It is marked by early impairment in skills such as visual-spatial awareness, visual perception, and praxis. People may also experience difficulties with literacy, numeracy, and other functions related to the posterior cortex. Patients often describe the problem as poor vision, but the severity of impairment is not explained by ocular findings alone.

Common complaints include trouble reading, locating objects in clutter, judging depth, driving, using stairs, navigating unfamiliar spaces, dressing, writing, or operating appliances. Some patients report that objects “disappear” in front of them. This might show problems with visual attention or higher-level visual processing. It’s not primarily about a visual field defect.

The syndrome may include features of Balint syndrome, Gerstmann syndrome, alexia, apraxia, visual agnosia, environmental disorientation, simultanagnosia, or impaired spatial construction. Memory, insight, and social behavior may be relatively preserved early. That preservation can be misleading. The patient might seem clear and aware, but they can’t do visual tasks that used to be automatic.

PCA is often due to Alzheimer’s disease pathology, but it should not be treated as synonymous with Alzheimer’s disease. The consensus framework separates the clinical syndrome from the disease-level attribution. 

A patient may have PCA from:

• Alzheimer’s disease
• Lewy body disease
• Corticobasal degeneration
• Prion disease
• Other rare causes

 The presence of early hallucinations, cognitive fluctuations, parkinsonism, asymmetric rigidity, alien limb phenomena, seizures, rapid progression, or prominent vascular lesions should broaden the differential diagnosis.

Structural MRI often shows atrophy in the back of the brain. This mainly happens in the occipital, parietal, and posterior temporal regions. FDG-PET may show posterior cortical hypometabolism. Amyloid PET, CSF Alzheimer’s disease biomarkers, and certain blood-based markers can help identify the biology of Alzheimer’s disease in specialty settings.

Primary Progressive Aphasia

Primary progressive aphasia is a neurodegenerative syndrome in which progressive language impairment is the leading symptom for much of the early disease course. It is not a single disease and should not be presented as a direct equivalent of Alzheimer’s disease.

The consensus classification identifies three main PPA variants:

• Semantic variant PPA
• Nonfluent/agrammatic variant PPA
• Logopenic variant PPA

 Each has a characteristic language profile, neuroanatomic pattern, and usual pathologic association.

Semantic variant PPA is characterized by loss of word and object meaning. Patients develop anomia, impaired single-word comprehension, and surface dyslexia or dysgraphia. Speech may remain fluent and grammatically intact early. Imaging often shows anterior temporal lobe atrophy, frequently with left-sided predominance. This variant is linked more to frontotemporal lobar degeneration than to Alzheimer’s disease.

Nonfluent/agrammatic variant PPA presents with effortful speech, agrammatism, apraxia of speech, or a combination of these features. Single-word comprehension is often relatively preserved early, while syntactically complex sentence comprehension becomes impaired. Imaging commonly shows involvement of the left inferior frontal, insular, premotor, or perisylvian regions. Underlying pathology is often frontotemporal lobar degeneration, although individual cases vary.

Logopenic variant PPA is the subtype of PPA most linked to Alzheimer’s disease. Patients show word-finding pauses, impaired sentence repetition, phonologic errors, and reduced verbal working memory. Single-word comprehension and motor speech are relatively preserved early compared with the semantic and nonfluent variants. Imaging often shows involvement of the left posterior temporal and inferior parietal regions.

In a patient with progressive language impairment, it is important to identify the PPA variant. This step is crucial and not just for description. It helps with differential diagnosis, guides biomarker selection, and indicates whether Alzheimer’s treatment is possible.

Diagnostic Approach

The diagnostic evaluation should begin with a careful syndrome-level formulation. The clinician should check whether the main syndrome is one of the following: visuospatial, language-led, amnestic, dysexecutive, behavioral, motor, or mixed. A care partner’s history is often essential. Patients may report issues like visual difficulty, clumsiness, anxiety, work failure, or loss of confidence. They might not recognize these as signs of cognitive decline.

Functional staging is the next step. Mild cognitive impairment means there’s a noticeable decline, but basic independence remains. However, complex tasks may take longer or be less reliable. Dementia implies cognitive decline that interferes with independence. This distinction is clinically important because anti-amyloid monoclonal antibodies are designed for early symptomatic Alzheimer’s disease. They mainly focus on mild cognitive impairment or mild dementia stages in the populations studied.

Standard cognitive screening tools may miss early atypical Alzheimer’s disease. The Mini-Mental State Examination and Montreal Cognitive Assessment can be useful as broad screens, but they may under-sample visual-perceptual, visual-spatial, praxis, and language-specific deficits. Normal or nearly normal screening results shouldn’t preclude evaluation if the history indicates worsening focal cortical dysfunction.

For suspected PCA, neuropsychological assessment should include visual perception, spatial processing, object recognition, reading, calculation, praxis, construction, and executive function. For suspected PPA, testing should include confrontation naming, single-word comprehension, repetition, motor speech, sentence comprehension, reading, writing, and connected speech analysis.

Structural MRI is usually the first-line imaging study. It helps rule out stroke, mass lesions, and subdural collections. It also checks for hydrocephalus and severe vascular disease. Additionally, it identifies other structural mimics. It helps identify various atrophy types. In PCA, you see posterior-predominant atrophy. For logopenic PPA, it detects left posterior temporoparietal atrophy. In semantic variant PPA, there is anterior temporal atrophy. At the same time, it shows left frontal-insular involvement in nonfluent/agrammatic PPA.

When results will change diagnosis, prognosis, counseling, treatment eligibility, or care planning, clinicians should use biomarker testing. Amyloid PET and CSF Aβ42/40, along with tau measures, remain established tools for confirming Alzheimer’s disease pathology. Blood-based biomarkers are quickly being used in practice. However, it’s important to interpret them in light of assay performance, clinical context, and local care protocols. They should not replace a careful neurologic assessment.

Differential Diagnosis

The differential diagnosis for PCA includes:

• Ophthalmologic disease
• Occipital stroke
• Mass lesion
• Dementia with Lewy bodies
• Corticobasal syndrome
• Prion disease
• Vascular cognitive impairment
• Inflammatory or autoimmune disease
• Medication or toxic-metabolic contributors.

Several features should prompt reconsideration of uncomplicated PCA due to Alzheimer’s disease. Abrupt onset suggests vascular or structural disease. Visual hallucinations, cognitive changes, REM sleep issues, or parkinsonism can signal Lewy body disease. Asymmetric rigidity, dystonia, myoclonus, alien limb phenomena, or marked apraxia may suggest corticobasal syndrome. Rapid progression should prompt evaluation for prion, inflammatory, malignant, infectious, or toxic-metabolic causes.

The differential diagnosis for PPA includes:

• Frontotemporal lobar degeneration
• Alzheimer’s disease
• Corticobasal degeneration
• Progressive supranuclear palsy
• Vascular lesions affecting language networks
• Structural lesions
• Psychiatric or functional mimics

 The language phenotype provides clues, but it does not prove the underlying pathology.

Pharmacologic Management

Medication decisions should be based on the likely disease biology and clinical stage, not the syndrome label alone.

Cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine are symptomatic treatments for Alzheimer’s disease dementia. Memantine is used for moderate to severe Alzheimer’s disease dementia. In PCA or logopenic PPA with confirmed or strongly suspected Alzheimer’s disease pathology, a cautious trial of a cholinesterase inhibitor may be reasonable. However, variant-specific trial evidence is limited, and the expected benefit should be framed modestly.

Patients receiving cholinesterase inhibitors should be monitored for several important side effects. Watch for nausea, diarrhea, anorexia, weight loss, vivid dreams, and insomnia. Other important side effects include bradycardia, syncope, and falls. Also, check for drug interactions that may increase the risk of bradycardia. This careful monitoring is crucial for patient safety. Memantine may cause dizziness, headache, constipation, and confusion, and renal dosing should be considered.

Cholinesterase inhibitors require special caution when frontotemporal dementia is suspected. In semantic variant PPA or nonfluent/agrammatic PPA, without Alzheimer’s biomarkers, the benefits are unclear. Some patients with frontotemporal dementia may exhibit more severe behavioral symptoms. This can include more impulsivity or disinhibition.

Anti-amyloid monoclonal antibodies require a separate treatment pathway. Lecanemab and donanemab are antibodies targeting amyloid-beta in Alzheimer’s disease. They should only be started in patients who have early symptoms and confirmed amyloid beta pathology. Patients with atypical presentations, such as PCA or logopenic PPA, are included only if they meet other criteria. These include clinical, biomarker, MRI, safety, and functional standards. Atypical phenotypes have less evidence than typical amnestic cases. So, it’s best to refer to a memory-disorders specialist or an anti-amyloid treatment program.

Before starting anti-amyloid therapy, clinicians should check:

• Baseline MRI findings
• Hemorrhage risk
• Anticoagulant and thrombolytic exposure
• Seizure history
• Infusion feasibility
• Patient goals
• Care-partner support

 APOE ε4 testing is not diagnostic, but it informs amyloid-related imaging abnormality risk counseling. Patients and care partners should understand that ARIA may not show symptoms, can resemble a stroke, and can, in rare cases, be serious or fatal.

Nonpharmacologic Management

Nonpharmacologic management is central in atypical Alzheimer’s disease. For PCA, occupational therapy and low-vision rehabilitation can help maintain function. 

Practical interventions are:

• Better lighting
• Less visual clutter
• High-contrast labels
• Contrasting stair edges
• Simple appliance interfaces
• Consistent object placement
• Verbal cues

 Driving should be addressed early because visual-spatial impairment may create risk even when memory appears preserved.

For PPA, early referral to speech-language pathology is essential. 

Therapy can involve several strategies, such as:

• Word retrieval techniques
• Script training
• Training for communication partners
• Augmentative and alternative communication
• Planning for future communication challenges

These methods help improve communication skills.

Patients in language-intensive jobs may need early counseling. They should get advice on work modification, disability planning, and role transitions. This support can help them adapt to changes in their work life.

Care planning should address medication administration, finances, driving, cooking, falls, firearms, workplace safety, communication access, caregiver burden, and advance care planning. Depression, anxiety, frustration, and loss of identity are common. These symptoms deserve direct treatment and should not be dismissed as secondary reactions.

Genetic and Family Counseling

Most cases of PCA and PPA are sporadic. Autosomal dominant Alzheimer’s disease can occur due to changes in APP, PSEN1, or PSEN2. It is rare but should be considered if someone has early-onset symptoms, a strong family history, or a pattern consistent with autosomal dominant inheritance.

Genetic testing should not be ordered casually. It requires pre-test counseling, post-test counseling, and discussion of implications for relatives. The clinician should also address psychological, insurance, employment, and family-planning implications.

APOE testing is different from testing for autosomal dominant Alzheimer’s disease. APOE ε4 is a risk marker, not a diagnostic test. Its most important role today is providing ARIA risk counseling before anti-amyloid monoclonal antibody therapy.

Practical Takeaways

Non-amnestic Alzheimer’s disease is often missed because the first complaint is not memory loss. Suspect PCA if progressive visual-spatial problems can’t be explained by eye disease. Logopenic variant PPA should be suspected when word-finding pauses and impaired sentence repetition dominate early language decline.

The clinician should first define the syndrome, then determine the likely pathology. PCA is often due to Alzheimer’s disease, but not always. PPA is a syndrome, and logopenic PPA is the subtype most strongly linked to Alzheimer’s disease.

Treatment should be realistic. Symptomatic Alzheimer’s drugs may be considered when Alzheimer’s disease biology is likely or confirmed, but evidence in atypical variants is limited. Anti-amyloid therapy requires amyloid confirmation, early symptomatic stage, baseline and surveillance MRI, ARIA counseling, and careful review of hemorrhage risk. Multidisciplinary rehabilitation, safety planning, and caregiver education remain essential whether or not the patient is eligible for disease-modifying therapy.

Table 1. Syndrome first, pathology second

Syndrome	Early clinical clue	Pathology note
Typical amnestic AD	Repeats questions, forgets recent events, impaired delayed recall	Usually AD when clinical syndrome and biomarkers align
Posterior cortical atrophy	Reading difficulty, visual crowding, depth errors, object-finding difficulty	Often AD, but Lewy body disease, corticobasal degeneration, prion disease, and other causes occur
Logopenic PPA	Word-finding pauses, impaired sentence repetition, phonologic errors	PPA subtype most strongly associated with AD pathology
Semantic variant PPA	Loss of word meaning, impaired single-word comprehension	More often frontotemporal lobar degeneration
Nonfluent/agrammatic PPA	Effortful speech, agrammatism, apraxia of speech	More often frontotemporal lobar degeneration or related pathology

Table 2. Practical diagnostic workflow

Step	Purpose	Clinician notes
Define the syndrome	Identify the dominant deficit	Visual-spatial, language-led, amnestic, dysexecutive, behavioral, motor, or mixed
Stage function	Determine MCI vs dementia	Important for counseling and treatment eligibility
Obtain care-partner history	Clarify progression and safety	Patients may under-report or mislabel symptoms
Perform targeted testing	Detect deficits missed by screens	Use visual-spatial testing for PCA and language testing for PPA
Order structural MRI	Exclude mimics and identify atrophy pattern	Look for posterior, temporoparietal, anterior temporal, or frontal-insular patterns
Use biomarkers selectively	Determine AD biology when clinically useful	Amyloid PET, CSF Aβ/tau, or validated blood biomarkers in appropriate settings
Reassess diagnosis longitudinally	Mixed syndromes evolve	New hallucinations, parkinsonism, motor asymmetry, or rapid decline should reopen the differential

Table 3. Medication and monitoring considerations

Therapy	Role	Key cautions
Donepezil, rivastigmine, galantamine	Symptomatic option when AD biology is likely or confirmed	GI effects, weight loss, bradycardia, syncope, falls, sleep disturbance
Memantine	Symptomatic option in moderate to severe AD dementia	Dizziness, constipation, confusion, renal dosing considerations
Lecanemab	Disease-modifying amyloid antibody for early symptomatic AD with confirmed amyloid pathology	ARIA risk, baseline MRI, scheduled MRI surveillance, ApoE counseling, hemorrhage risk review
Donanemab	Disease-modifying amyloid antibody for early symptomatic AD with confirmed amyloid pathology	ARIA risk, baseline MRI, scheduled MRI surveillance, ApoE counseling, hemorrhage risk review
Cholinesterase inhibitors in suspected FTD	Usually avoid or use only with caution	May worsen impulsivity or disinhibition in some FTD patients
OT, low-vision rehabilitation	Core PCA management	Falls, driving, home safety, visual clutter, contrast cues
Speech-language pathology	Core PPA management	Communication strategies, AAC planning, care-partner training

References

Atri, A., Dickerson, B. C., Clevenger, C., Karlawish, J., Knopman, D., Lin, P. J., Norman, M., Onyike, C., Sano, M., Scanland, S., & Carrillo, M. (2025). Alzheimer’s Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer’s Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care. Alzheimer’s & Dementia, 21(6), e14333. doi: 10.1002/alz.14333

Benson, D. F., Davis, R. J., & Snyder, B. D. (1988). Posterior cortical atrophy. Archives of Neurology, 45(7), 789-793. doi: 10.1001/archneur.1988.00520310107024

Crutch, S. J., Schott, J. M., Rabinovici, G. D., Murray, M., Snowden, J. S., van der Flier, W. M., Dickerson, B. C., Vandenberghe, R., Ahmed, S., Bak, T. H., Boeve, B. F., Butler, C., Cappa, S. F., Ceccaldi, M., de Souza, L. C., Dubois, B., Graff-Radford, J., Graff-Radford, N. R., Hof, P. R., … Fox, N. C. (2017). Consensus classification of posterior cortical atrophy. Alzheimer’s & Dementia, 13(8), 870-884. doi: 10.1016/j.jalz.2017.01.014

Dickerson, B. C., Atri, A., Clevenger, C., Karlawish, J., Knopman, D., Lin, P. J., Norman, M., Onyike, C., Sano, M., Scanland, S., & Carrillo, M. (2025). The Alzheimer’s Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer’s Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care. Alzheimer’s & Dementia, 21(6), e14337. doi: 10.1002/alz.14337

Eisai Inc. (2025). LEQEMBI (lecanemab-irmb) injection, for intravenous use; LEQEMBI IQLIK (lecanemab-irmb) injection, for subcutaneous use: Prescribing information. Revised August 2025. U.S. Food and Drug Administration.

Eli Lilly and Company. (2025). KISUNLA (donanemab-azbt) injection, for intravenous use: Prescribing information. Revised July 2025. U.S. Food and Drug Administration.

Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., Manes, F., Dronkers, N. F., Vandenberghe, R., Rascovsky, K., Patterson, K., Miller, B. L., Knopman, D. S., Hodges, J. R., Mesulam, M. M., & Grossman, M. (2011). Classification of primary progressive aphasia and its variants. Neurology, 76(11), 1006-1014. doi: 10.1212/WNL.0b013e31821103e6

Jack, C. R., Jr., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., Molinuevo, J. L., Rafii, M. S., Scheltens, P., Siemers, E., Snyder, H. M., Sperling, R., Teunissen, C. E., & Carrillo, M. C. (2024). Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimer’s & Dementia, 20(8), 5143-5169. doi: 10.1002/alz.13859

Koedam, E. L. G. E., Lauffer, V., van der Vlies, A. E., van der Flier, W. M., Scheltens, P., & Pijnenburg, Y. A. L. (2010). Early-versus late-onset Alzheimer’s disease: More than age alone. Journal of Alzheimer’s Disease, 19(4), 1401-1408. doi: 10.3233/JAD-2010-1337

Lehmann, M., Crutch, S. J., Ridgway, G. R., Ridha, B. H., Barnes, J., Warrington, E. K., Rossor, M. N., & Fox, N. C. (2011). Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer’s disease. Neurobiology of Aging, 32(8), 1466-1476. doi: 10.1016/j.neurobiolaging.2009.08.017

Mesulam, M. M., Weintraub, S., Rogalski, E. J., Wieneke, C., Geula, C., & Bigio, E. H. (2014). Asymmetry and heterogeneity of Alzheimer’s and frontotemporal pathology in primary progressive aphasia. Brain, 137(4), 1176-1192. doi: 10.1093/brain/awu024

Ossenkoppele, R., Cohn-Sheehy, B. I., La Joie, R., Vogel, J. W., Möller, C., Lehmann, M., van Berckel, B. N. M., Seeley, W. W., Pijnenburg, Y. A., Gorno-Tempini, M. L., Kramer, J. H., Barkhof, F., Rosen, H. J., van der Flier, W. M., Jagust, W. J., Miller, B. L., Scheltens, P., & Rabinovici, G. D. (2015). Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer’s disease. Human Brain Mapping, 36(11), 4421-4437. doi: 10.1002/hbm.22927

Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., Vogel, J., Santos, M., Miller, Z. A., Bettcher, B. M., Vossel, K. A., Kramer, J. H., Gorno-Tempini, M. L., Miller, B. L., Jagust, W. J., & Rabinovici, G. D. (2016). Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain, 139(5), 1551-1567. doi: 10.1093/brain/aww027

Palmqvist, S., Whitson, H. E., Allen, L. A., Suarez-Calvet, M., Galasko, D., Karikari, T. K., Okrahvi, H., Paczynski, M., Schindler, S. E., Teunissen, C. E., Zetterberg, H., Carrillo, M. C., Edelmayer, R. M., Mahinrad, S., McAteer, M. B., Kahale, L. A., Pahlke, S., & Tampi, M. P. (2025). Alzheimer’s Association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings. Alzheimer’s & Dementia, 21(7), e70535. doi: 10.1002/alz.70535

Rohrer, J. D., Rossor, M. N., & Warren, J. D. (2010). Syndromes of nonfluent primary progressive aphasia: A clinical and neurolinguistic analysis. Neurology, 75(7), 603-610. doi: 10.1212/WNL.0b013e3181ed9c6b

Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., Collins, E. C., Solomon, P., Salloway, S., Apostolova, L. G., Hansson, O., Ritchie, C., Brooks, D. A., Mintun, M. A., Skovronsky, D. M., & TRAILBLAZER-ALZ 2 Investigators. (2023). Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA, 330(6), 512-527. doi: 10.1001/jama.2023.13239

van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., & Iwatsubo, T. (2023). Lecanemab in early Alzheimer’s disease. The New England Journal of Medicine, 388(1), 9-21. doi: 10.1056/NEJMoa2212948